Severe immune thrombocytopenic purpura in critical COVID-19

Int J Hematol. 2020 Nov;112(5):746-750. doi: 10.1007/s12185-020-02931-9. Epub 2020 Jul 1.

Abstract

COVID-19 is a new disease with many undescribed clinical manifestations. We report herein a case of severe immune thrombocytopenic purpura (ITP) in a critical COVID-19 patient. A patient presented a severe episode of immune thrombocytopenia (< 10 × 109/L) 20 days after admission for a critical COVID-19. This thrombocytopenia was associated with a life-threatening bleeding. Response to first-line therapies was delayed as it took up to 13 days after initiation of intravenous immunoglobulin and high-dose dexamethasone to observe an increase in platelet count. COVID-19 may be associated with late presenting severe ITP. Such ITP may also be relatively resistant to first-line agents. Hematological manifestations of COVID-19, such as the ones associated with life-threatening bleeding, must be recognized.

Keywords: Bleeding; COVID-19; Corticosteroids; Immunoglobulin; Thrombocytopenia.

Publication types

  • Case Reports

MeSH terms

  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • Combined Modality Therapy
  • Coronavirus Infections / complications*
  • Coronavirus Infections / drug therapy
  • Dexamethasone / therapeutic use
  • Hemorrhage / etiology
  • Humans
  • Immunoglobulins, Intravenous
  • Intracranial Hemorrhages / etiology
  • Male
  • Middle Aged
  • Pandemics*
  • Pneumonia, Staphylococcal / etiology
  • Pneumonia, Ventilator-Associated / etiology
  • Pneumonia, Viral / complications*
  • Pulmonary Atelectasis / etiology
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy
  • Purpura, Thrombocytopenic, Idiopathic / etiology*
  • Purpura, Thrombocytopenic, Idiopathic / therapy
  • Respiratory Distress Syndrome / etiology
  • Respiratory Distress Syndrome / therapy
  • SARS-CoV-2

Substances

  • Immunoglobulins, Intravenous
  • Dexamethasone